Citations 2
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells
Tanno, Toshihiko, Lim, Yiting , Wang, Qiuju , Chesi, Marta , Bergsagel, P. Leif , Matthews, Geoff, Johnstone, Ricky W. , Borrello, Ivan , Huff, Carol Ann , Matsui, William , Bergsagel, P. Leif , Ghosh, Nilanjan
Blood | December 18, 2013 | Volume: 123 | Issue: 5 | Pages: 725-733
Key Points The tumor microenvironment drives myeloma cell clonogenic growth and self-renewal through GDF15.
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
Kasamon, Yvette L. , Jacene, Heather A. , Gocke, Christopher D. , Swinnen, Lode J., Gladstone, Douglas E. , Perkins, Brandy, Link, Brian K. , Popplewell, Leslie , Herman, Joseph M. , Matsui, William , Jones, Richard J. , Ambinder, Richard F. , Habermann, Thomas M. , Link, Brian K , Ambinder, Richard F
Blood | February 17, 2012 | Volume: 119 | Issue: 18 | Pages: 4129-4132
Abstract In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20+ Hodgkin and Reed-Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94% for AVD and 79% for bleomycin. After 6 cycles, 81% of patients were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83% and 98%, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV+ tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as NCT00369681.